KOLMAR-BNH
22.4.2024 05:00:33 CEST | Business Wire | Press release
Hemohim is garnering remarkable popularity in the global market as Korea's one of the leading functional foods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418277251/en/
Kolmar BNH Sejong Factory (Photo: Kolmar BNH)
Hemohim is developed through an eight-year collaboration between Kolmar BNH (KOSDAQ: 200130) and the Korea Atomic Energy Research Institute, with an investment of KRW 5 billion. It was extracted from raw materials of angelica gigas, cnidium officinale, and paeonia japonica, which have been traditionally used in herbal medicine. Kolmar BNH performed tests on humans to confirm the safety and efficacy of its main ingredient, ‘HemoHIM Extract complex of Angelica gigas, etc.’, and was recognized by the Ministry of Food and Drug Safety of Korea in 2006 for its immune-boosting properties.
Distributed by Atomy, a customer of Kolmar BNH, Hemohim has sold over KRW 2 trillion worth of products in just 17 years since its launch, making it the nation’s best-selling individually approved health functional food. With strong demand from many countries like Australia, the US, and Thailand, Hemohim has expanded its global presence to over 20 countries.
Following a rigorous review process, Hemohim received approval from the Korean Ministry of Food and Drug Safety as the nation’s first individually approved health supplement product designed to enhance immune function.
Ranking the second-highest exported product after red ginseng in Korea, Hemohim is the leading individually approved health functional food ingredient. Kolmar BNH, propelled by Hemohim's success, was honored with the '200 Million Dollar Export Tower' at the 2021 'Trade Day' ceremony hosted by the Korea International Trade Association.
Kolmar BNH is making R&D efforts to sharpen its material competitiveness, as evidenced by the 'Hemohim Sustaining Technology Development Project.' After six years of endeavors, it obtained a fatigue recovery function last year, solidifying Hemohim's status as a dual-functional food with immune enhancement and fatigue recovery.
To further reach the European market, Kolmar BNH has developed HemohimG, tailored to suit European preferences in tastes and aroma. HemohimG is a product made for exports that follow the food regulations of each country. It is now poised for export to the UK and Turkey.
A Kolmar BNH official stated, "Hemohim represents Korea's top health functional food, backed by research capabilities and manufacturing prowess. After its success in Korea over the past 16 years, Hemohim is ready to leave its footprint on the global market."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418277251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
